"On April 9, 2021, the new recombinant coronavirus vaccine Sinopharm of Chinese National Institute of Biological Sciences received approval for clinical trials from the National Health Products Administration," said in a statement.
The report notes that the other two vaccines were inactivated (with the virus "killed"). The new one is recombinant.
"The recombinant vaccine for the coronavirus is based on the natural structural characteristics of the novel receptor-binding domain (RBD) of the coronavirus spike protein (S-protein) and uses structural biology and computational biology for independent design and development," the company said.
On April 1, the World Health Organization recognized the effectiveness of the coronavirus vaccine from the Chinese pharmaceutical companies Sinopharm and Sinovac. The organization said that these drugs meet the requirements of the WHO.
According to preliminary data from clinical trials conducted in different countries, the effectiveness of the Sinopharm vaccine is approximately 79.34%, while the effectiveness of Sinovac ranges from 50.65 to 83.5%.